



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 6680

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

14 May 2021

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Oncology treatments.

You asked:

- 1. How many patients were treated (for any condition) in the past 6 months with:*
 - a. Abiraterone*
 - b. Apalutamide*
 - c. Cabazitaxel*
 - d. Darolutamide*
 - e. Docetaxel*
 - f. Enzalutamide*
 - g. Ruxolitinib*
- 2. Please provide the total number of patients treated in the last 6 months for*
 - a. Myelofibrosis (ICD10 code D47.4)*
 - b. Myelofibrosis (ICD10 code D47.4) – patients over the age 65*
 - c. Prostate cancer*
 - d. Metastatic prostate cancer*
- 3. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?*
 - a. Of these patients, how many were treated in the past 6 months with Hydroxyurea?*
 - b. Of these patients, how many have received no active treatment in the past 6 months?*
- 4. How many metastatic prostate cancer patients were treated in the past 6 months with:*
 - a. Abiraterone*
 - b. Apalutamide*
 - c. Cabazitaxel*
 - d. Darolutamide*

- e. *Docetaxel*
- f. *Enzalutamide*

Trust response:

1. How many patients were treated (for any condition) in the past 6 months with:

- a. Abiraterone 51
- b. Apalutamide 0
- c. Cabazitaxel 8
- d. Darolutamide 2
- e. Docetaxel 50 (alone or in combination)
- f. Enzalutamide 59
- g. Ruxolitinib 20

2a and 2b. We do not record D codes on our systems. We do not have this information.

2c and 2d – We cannot easily distinguish patients having treatment for metastatic cancer. Patients with treatment against a prostate diagnosis break down as follows; broken down by treatment type.

Chemo only	101
Chemo & RT	28
RT only	273

3. We do not record D codes on our systems. We do not have this information.

4) We cannot reliably identify the metastatic prostate patients so cannot return this.